Inclusion Criteria  Age greater than or equal to (>=)18 years.  Criteria for disease state.  Dose-escalation tumor histologies: Dose escalation will begin by initially enrolling participants with histologically or pathologically confirmed, unresectable, locally advanced or metastatic cancers. Cohort-expansion tumor histologies: Participants will be eligible if they have histologically proven, unresectable, locally advanced or metastatic malignant neoplasms. Eastern Cooperative Oncology Group performance status (less than or equal to [<=]) 1. Measurable disease per modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1 and documented by CT and/or MRI except for participants with PC with only bone metastases.  Exclusion Criteria  History of known autoimmune disease. Major surgery or traumatic injury within 8 weeks before the first dose of TAK-280. Unhealed wounds from surgery or injury. Ongoing or active infection of Grade >=2. Oxygen saturation < 92% on room air at screening or during C1D1 predose assessment. Inflammatory process that has not resolved >= 4 weeks before the first dose of study drug. participants with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of their duration. Vaccination with any live virus vaccine within 4 weeks or other vaccines within 2 weeks before the initiation of study drug. Inactivated annual influenza vaccination is allowed. Known hypersensitivity to TAK-280 or any excipient.